{"id":"active-comparator2-telmisartan","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Dizziness"},{"rate":"7-9","effect":"Upper respiratory tract infection"},{"rate":"3-5","effect":"Back pain"},{"rate":"3-5","effect":"Pharyngitis"},{"rate":"1-3","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1017","moleculeType":"Small molecule","molecularWeight":"514.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Telmisartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and other tissues. By blocking angiotensin II signaling, it causes vasodilation and reduces aldosterone secretion, leading to decreased blood pressure and improved renal perfusion. This mechanism also provides cardioprotective and renoprotective effects in hypertensive and diabetic patients.","oneSentence":"Telmisartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:13.460Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Cardiovascular risk reduction in patients with hypertension"}]},"trialDetails":[{"nctId":"NCT04218552","phase":"PHASE2","title":"Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2020-02-25","conditions":"Hypertension,Essential","enrollment":176},{"nctId":"NCT04659070","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia","status":"UNKNOWN","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2020-07-15","conditions":"Primary Hypercholesterolemia, Hypertension","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Active comparator2 : Telmisartan","genericName":"Active comparator2 : Telmisartan","companyName":"Hanlim Pharm. Co., Ltd.","companyId":"hanlim-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Telmisartan blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and reducing blood pressure. Used for Hypertension, Cardiovascular risk reduction in patients with hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}